Altimmune, Inc. (NASDAQ:ALT) CFO Gregory L. Weaver Acquires 10,000 Shares of Stock

Altimmune, Inc. (NASDAQ:ALT) CFO Gregory L. Weaver acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were purchased at an average price of $5.20 per share, with a total value of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $52,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $5.92 on Friday. The company has a market capitalization of $455.92 million, a PE ratio of -3.82 and a beta of 0.87. The business has a fifty day moving average price of $6.48 and a two-hundred day moving average price of $7.11. Altimmune, Inc. has a 1 year low of $5.14 and a 1 year high of $11.16.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. Sell-side analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ALT shares. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Monday, March 3rd. William Blair reiterated a “market perform” rating on shares of Altimmune in a report on Friday. Finally, Stifel Nicolaus started coverage on Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.83.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ALT. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Altimmune by 119.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 40,705 shares of the company’s stock valued at $250,000 after buying an additional 22,188 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Altimmune during the 3rd quarter worth about $207,000. Charles Schwab Investment Management Inc. lifted its holdings in Altimmune by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after purchasing an additional 4,772 shares in the last quarter. Larson Financial Group LLC purchased a new stake in Altimmune during the 3rd quarter worth about $31,000. Finally, Summit Financial Wealth Advisors LLC lifted its holdings in Altimmune by 65.1% during the 3rd quarter. Summit Financial Wealth Advisors LLC now owns 45,918 shares of the company’s stock worth $282,000 after purchasing an additional 18,113 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.